NANO.PA

Nanobiotix S.A. [NANO.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NANO.PA Stock Summary

Top 10 Correlated ETFs

NANO.PA

Top 10 Correlated Stocks

NANO.PA

In the News

NANO.PA Financial details

Company Rating
-
Market Cap
246.86M
Income
-101.72M
Revenue
9.4M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-4.23
Forward P/E
-
PEG
-0.36
P/S
-
P/B
-8.93
P/C
-
P/FCF
-9.09
Quick Ratio
1.3
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.14%
Revenue last 5Y
6.54%
Revenue Q/Q
-4.47%
EPS Q/Q
-9.09%
-
-
-
-
SMA20
-13.06%
SMA50
-23.1%
SMA100
-1.35%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
44740%
ROC
-2.14%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.612-10.4
52W High
-70.2%
52W Low
+198%
RSI
45.85
Rel Volume
2.34
Avg Volume
58.71K
Volume
137.41K
Perf Week
-0.67%
Perf Month
1.02%
Perf Quarter
-23%
Perf Half Y
-29.05%
-
-
-
-
Beta
1.252
-
-
Volatility
0.05%, 0.23%
Prev Close
4.2%
Price
2.98
Change
4.2%

Something similar

Top by Market Cap
DHR-PB
NVDA
NVD.DE
GOOG
TSLA
Top Correlated ETFs
ALYU.L
WOOD.L
CASH.DE
CNAA.DE
ESIH.DE
Top Correlated Stocks
0QAV.L
0QN2.L
ASCN.SW
3883.HK
1338.TW
Similar Market Cap
ETLH.DE
CPS
1598.HK
CNE.L
VARN.SW

Company Profile

Healthcare Biotechnology
  • Volume Average 58.71K
  • Market Capitalization 246.86M
  • Employee 101
  • CEO Mr. Laurent Levy Ph.D.
  • Headquarters Paris,FR
  • IPO Date 2012-10-29
  • Website https://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.